

Robert A Hauser

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5443797/robert-a-hauser-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

225
papers

15,429
citations

60
h-index

121
g-index

234
ext. papers

17,822
ext. citations

6.9
avg, IF

6.34
L-index

#	Paper	IF	Citations
225	Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. <i>Nature Medicine</i> , 2008 , 14, 504-6	50.5	1209
224	The Parkinson Progression Marker Initiative (PPMI). <i>Progress in Neurobiology</i> , 2011 , 95, 629-35	10.9	793
223	Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. <i>New England Journal of Medicine</i> , 1995 , 332, 1118-24	59.2	764
222	A double-blind, delayed-start trial of rasagiline in Parkinson's disease. <i>New England Journal of Medicine</i> , 2009 , 361, 1268-78	59.2	694
221	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. <i>Annals of Neurology</i> , 2003 , 54, 93-101	9.4	691
220	High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. <i>Annals of Neurology</i> , 1997 , 42, 292-9	9.4	451
219	Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. <i>Annals of Neurology</i> , 1995 , 38, 379-88	9.4	370
218	Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. <i>Archives of Neurology</i> , 1999 , 56, 179-87		292
217	Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. <i>Neurology</i> , 2003 , 61, 297-303	6.5	264
216	Long-term evaluation of deep brain stimulation of the thalamus. <i>Journal of Neurosurgery</i> , 2006 , 104, 506-12	3.2	259
215	A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. <i>JAMA Neurology</i> , 2014 , 71, 543-52	17.2	239
214	Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. <i>Movement Disorders</i> , 1998 , 13, 383-93	7	232
213	Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. <i>Movement Disorders</i> , 2008 , 23, 2303-6	7	212
212	Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. <i>Movement Disorders</i> , 2005 , 20, 783-91	7	210
211	KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. <i>American Journal of Psychiatry</i> , 2017 , 174, 476-484	11.9	209
210	Manganese intoxication and chronic liver failure. <i>Annals of Neurology</i> , 1994 , 36, 871-5	9.4	204
209	Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. <i>Movement Disorders</i> , 2008 , 23, 690-9	7	187

208	Pramipexole-induced somnolence and episodes of daytime sleep. <i>Movement Disorders</i> , 2000 , 15, 658-637	7	187
207	Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. <i>Movement Disorders</i> , 2005 , 20, 726-33	7	186
206	Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. <i>Neurology</i> , 2017 , 88, 2003-2010	6.5	184
205	A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. <i>Clinical Neuropharmacology</i> , 2000 , 23, 75-81	1.4	182
204	Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. <i>New England Journal of Medicine</i> , 1999 , 341, 988-92	59.2	177
203	Hypertensive encephalopathy. Magnetic resonance imaging demonstration of reversible cortical and white matter lesions. <i>Archives of Neurology</i> , 1988 , 45, 1078-83		177
202	Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Psychiatry</i> , 2017 , 4, 595-604	23.3	174
201	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. <i>Movement Disorders</i> , 2007 , 22, 2409-17	7	174
200	Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. <i>Movement Disorders</i> , 2008 , 23, 2177-85	7	174
199	Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. <i>Lancet Neurology</i> , 2011 , 10, 221-9	24.1	159
198	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. <i>Lancet Neurology</i> , 2011 , 10, 415-23	24.1	159
197	Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. <i>Lancet Neurology</i> , 2013 , 12, 346-56	24.1	149
196	A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. <i>Movement Disorders</i> , 2008 , 23, 2194-201	7	138
195	Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. <i>Archives of Neurology</i> , 2006 , 63, 1756-60		137
194	Parkinson's disease home diary: further validation and implications for clinical trials. <i>Movement Disorders</i> , 2004 , 19, 1409-13	7	136
193	Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. <i>Movement Disorders</i> , 2004 , 19, 426-32	7	128
192	Sertraline for the treatment of depression in Parkinson's disease. <i>Movement Disorders</i> , 1997 , 12, 756-9	7	124
191	Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. <i>Lancet Neurology</i> , 2011 , 10, 509-19	24.1	122

190	Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2017 , 74, 216-224	17.2	116
189	Levodopa: past, present, and future. <i>European Neurology</i> , 2009 , 62, 1-8	2.1	114
188	Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. <i>Nature Reviews Drug Discovery</i> , 2018 , 17, 804-822	64.1	114
187	Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. <i>Movement Disorders</i> , 2000 , 15, 305-8	7	113
186	ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2017 , 74, 941-949	17.2	112
185	Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 564-73	7	108
184	Determination of minimal clinically important change in early and advanced Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 813-8	7	107
183	Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). <i>Movement Disorders</i> , 2015 , 30, 646-54	7	105
182	Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). <i>Movement Disorders</i> , 2017 , 32, 1701-1709	7	103
181	Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 541-50	7	99
180	Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. <i>Lancet Neurology</i> , 2014 , 13, 767-76	24.1	97
179	Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. <i>Movement Disorders</i> , 2004 , 19, 916-23	7	97
178	Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 979-83	7	96
177	Blood manganese correlates with brain magnetic resonance imaging changes in patients with liver disease. <i>Canadian Journal of Neurological Sciences</i> , 1996 , 23, 95-8	1	87
176	NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. <i>Movement Disorders</i> , 2015 , 30, 1681-7	7	82
175	Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 2246-52	7	77
174	Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). <i>Neurology</i> , 2012 , 79, 163-9	6.5	77
173	Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. <i>Movement Disorders</i> , 2010 , 25, 1131-42	7	75

172	A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. <i>Movement Disorders</i> , 2007 , 22, 279-82	7	74
171	Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 2542-9	7	69
170	Wearing-off scales in Parkinson's disease: critique and recommendations. <i>Movement Disorders</i> , 2011 , 26, 2169-75	7	68
169	Head injury, Synuclein Rep1, and Parkinson's disease. <i>Annals of Neurology</i> , 2012 , 71, 40-8	9.4	66
168	Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 858-66	7	66
167	The independent influence of apathy and depression on cognitive functioning in Parkinson's disease. <i>Neuropsychology</i> , 2010 , 24, 721-30	3.8	62
166	A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1356-65	7	61
165	Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. <i>Movement Disorders</i> , 2005 , 20, 1205-9	7	60
164	Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. <i>Movement Disorders</i> , 2002 , 17, 961-8	7	59
163	Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 115-6	7	57
162	Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. <i>European Neurology</i> , 2008 , 60, 57-66	2.1	55
161	Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1366-72	7	54
160	Efficacy, tolerability, and immunogenicity of onabotulinumtoxin in a randomized, double-blind, placebo-controlled trial for cervical dystonia. <i>Clinical Neuropharmacology</i> , 2012 , 35, 208-14	1.4	54
159	A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. <i>Movement Disorders</i> , 2007 , 22, 1660-3	7	54
158	End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. <i>Clinical Neuropharmacology</i> , 2006 , 29, 312-21	1.4	54
157	Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. <i>Movement Disorders</i> , 2000 , 15, 485-489	7	54
156	Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Neurology</i> , 2019 , 18, 145-154	24.1	52
155	Magnetic resonance imaging of corticobasal degeneration 1996 , 6, 222-6		50

154	Hyperactivity and hypoactivity in a rat model of Huntington's disease: the systemic 3-nitropropionic acid model. <i>Brain Research Protocols</i> , 1997 , 1, 253-7		48
153	Modafinil treatment of pramipexole-associated somnolence. <i>Movement Disorders</i> , 2000 , 15, 1269-71	7	47
152	A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III). <i>Annals of Clinical and Translational Neurology</i> , 2017 , 4, 360-368	5.3	46
151	Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. <i>Drugs and Aging</i> , 2005 , 22, 471-82	4.7	46
150	Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. <i>Neurology</i> , 1998 , 51, 912-3	6.5	46
149	Future treatments for Parkinson's disease: surfing the PD pipeline. <i>International Journal of Neuroscience</i> , 2011 , 121 Suppl 2, 53-62	2	45
148	Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release. <i>Parkinson's Disease</i> , 2014 , 2014, 467131	2.6	44
147	The nosology of tardive syndromes. <i>Journal of the Neurological Sciences</i> , 2018 , 389, 10-16	3.2	42
146	Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 359-65	7	42
145	Levodopa/carbidopa/entacapone (Stalevo). <i>Neurology</i> , 2004 , 62, S64-71	6.5	42
144	Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Neurology</i> , 2020 , 19, 135-144	24.1	42
143	Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease. <i>Neurology</i> , 2017 , 88, 2198-2206	6.5	41
142	Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease. <i>Metabolic Brain Disease</i> , 1998 , 13, 43-53	3.9	41
141	[123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes. <i>Journal of Neuroimaging</i> , 2012 , 22, 225-30	2.8	40
140	Duodenal levodopa infusion for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 657-64	4	40
139	A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group. <i>Movement Disorders</i> , 1998 , 13, 643-7	7	39
138	ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. <i>Journal of Parkinson's Disease</i> , 2017 , 7, 511-522	5.3	37
137	Levodopa response in early Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 2328-36	7	36

136	Essential tremor. Epidemiology, diagnosis, and treatment. <i>Neurologist</i> , 2004 , 10, 250-8	1.6	36
135	Long-term effects of rasagiline and the natural history of treated Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1489-1496	7	35
134	Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension. <i>Clinical Neuropharmacology</i> , 2016 , 39, 220-6	1.4	35
133	Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. <i>Clinical Neuropharmacology</i> , 2010 , 33, 5-10	1.4	33
132	Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. <i>Movement Disorders</i> , 2011 , 26, 1464-76	7	32
131	Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment. <i>Current Neurology and Neuroscience Reports</i> , 2007 , 7, 302-10	6.6	31
130	Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 2326-32	7	30
129	Caffeine and progression of Parkinson disease. <i>Clinical Neuropharmacology</i> , 2008 , 31, 189-96	1.4	30
128	Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. <i>JAMA Neurology</i> , 2016 , 73, 102-10	17.2	29
127	Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. <i>Clinical Neuropharmacology</i> , 2012 , 35, 174-81	1.4	29
126	The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. <i>Clinical Neuropharmacology</i> , 2006 , 29, 106-114		29
125	Phenomenology and treatment of tremor disorders. <i>Neurologic Clinics</i> , 2001 , 19, 651-80, vii	4.5	29
124	Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease. <i>Movement Disorders</i> , 1993 , 8, 512-4	7	29
123	Pharmacokinetics of ADS-5102 (Amantadine) Extended-Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 77-88	6.2	27
122	Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 738-46	7	27
121	Adult Chediak-Higashi parkinsonian syndrome with dystonia. <i>Movement Disorders</i> , 2000 , 15, 705-8	7	27
120	Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease. <i>Movement Disorders</i> , 2006 , 21, 1998-2001	7	24
119	Deep brain stimulation of the internal segment of the globus pallidus in delayed runaway dyskinesia. <i>Archives of Neurology</i> , 2006 , 63, 1181-4		24

118	Bilateral human fetal striatal transplantation in Huntington's disease. <i>Neurology</i> , 2002 , 58, 1704; author reply 1704	6.5	24
117	Dyskinesia matters. <i>Movement Disorders</i> , 2020 , 35, 392-396	7	24
116	Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019 , 64, 175-180	3.6	23
115	Advances in the pharmacologic management of early Parkinson disease. <i>Neurologist</i> , 2007 , 13, 126-32	1.6	23
114	Impact of non-motor symptoms in Parkinson's disease: a PMDAAlliance survey. <i>Neuropsychiatric Disease and Treatment</i> , 2019 , 15, 2205-2212	3.1	22
113	Long-term efficacy of rasagiline in early Parkinson's disease. <i>International Journal of Neuroscience</i> , 2010 , 120, 404-8	2	22
112	Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease. <i>Clinical Neuropharmacology</i> , 2006 , 29, 322-30	1.4	22
111	Substantial improvement in a Meige's syndrome patient with levetiracetam treatment. <i>Movement Disorders</i> , 2004 , 19, 1518-21	7	21
110	Translocation breakpoint in two unrelated Tourette syndrome cases, within a region previously linked to the disorder. <i>Human Genetics</i> , 2003 , 113, 154-61	6.3	21
109	Sertraline-induced exacerbation of tics in Tourette's syndrome. <i>Movement Disorders</i> , 1995 , 10, 682-4	7	20
108	Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. <i>Journal of the Neurological Sciences</i> , 2017 , 377, 137-143	3.2	19
107	Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls 2020 , 11, 679-691		19
106	New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy. <i>Parkinsonism and Related Disorders</i> , 2009 , 15 Suppl 3, S17-21	3.6	19
105	Prevalence and treatment of non-motor symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007 , 13, 545	3.6	19
104	Levetiracetam for the treatment of generalized dystonia. <i>Parkinsonism and Related Disorders</i> , 2005 , 11, 469-71	3.6	19
103	Cyclosporine-A increases locomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism: relevance to neural transplantation. <i>World Neurosurgery</i> , 1996 , 46, 384-8		19
102	Design of a cluster-randomized minority recruitment trial: RECRUIT. <i>Clinical Trials</i> , 2017 , 14, 286-298	2.2	18
101	Tardive dyskinesia: Out of the shadows. <i>Journal of the Neurological Sciences</i> , 2018 , 389, 1-3	3.2	18

100	An update on Parkinson's disease: improving patient outcomes. <i>American Journal of Medicine</i> , 2014 , 127, S3	2.4	18
99	IPX066: a novel carbidopa-levodopa extended-release formulation. <i>Expert Review of Neurotherapeutics</i> , 2012 , 12, 133-40	4.3	18
98	Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease. <i>Clinical Neuropharmacology</i> , 2009 , 32, 48-50	1.4	18
97	Optimizing bioavailability in the treatment of Parkinson's disease. <i>Neuropharmacology</i> , 2007 , 53, 791-800	9.5	18
96	Caffeine, creatine, GRIN2A and Parkinson's disease progression. <i>Journal of the Neurological Sciences</i> , 2017 , 375, 355-359	3.2	17
95	Transplantation of human fetal striatal tissue in Huntington's disease: rationale for clinical studies. <i>Novartis Foundation Symposium</i> , 2000 , 231, 129-38; discussion 139-47		17
94	Pregabalin (Lyrica) in the treatment of essential tremor. <i>Movement Disorders</i> , 2007 , 22, 139-41	7	17
93	Use of nutritional supplements in Parkinson's disease patients. <i>Movement Disorders</i> , 2006 , 21, 1098-101	7	17
92	A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 783-789	7	16
91	Clozapine withdrawal symptoms in a Parkinson's disease patient. <i>Movement Disorders</i> , 2002 , 17, 1365-7	7	16
90	Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. <i>Journal of Parkinson & Disease</i> , 2017 , 7, 117-127	5.3	15
89	Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 1317-1323	5.5	15
88	Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease. <i>International Journal of Neuroscience</i> , 2011 , 121, 246-53	2	15
87	Levetiracetam-induced parkinsonism in a Huntington disease patient. <i>Clinical Neuropharmacology</i> , 2005 , 28, 188-90	1.4	15
86	Clinical trials aimed at detecting neuroprotection in Parkinson's disease. <i>Neurology</i> , 2006 , 66, S58-68	6.5	15
85	Medical Management and Prevention of Motor Complications in Parkinson's Disease. <i>Neurotherapeutics</i> , 2020 , 17, 1339-1365	6.4	15
84	Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials. <i>Annals of Pharmacotherapy</i> , 2018 , 52, 1182-1194	2.9	15
83	Chorea in a patient with cerebral palsy: treatment with levetiracetam. <i>Movement Disorders</i> , 2005 , 20, 762-4	7	14

82	Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. <i>American Journal of Cardiology</i> , 2017 , 119, 1111-1115	3	13
81	Carbidopa levodopa enteral suspension. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2807-17	4	13
80	Istradefylline - a first generation adenosine A antagonist for the treatment of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 317-333	4.3	13
79	EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 543-558	5.3	12
78	Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 627-634	2.2	12
77	Practical Evaluation and Management of Insomnia in Parkinson's Disease: A Review. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 250-266	2.2	11
76	ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia. <i>JAMA Neurology</i> , 2017 , 74, 1507-1508	17.2	11
75	Article Commentary: Infectious Issues in Human Fetal Neural Transplantation. <i>Cell Transplantation</i> , 1997 , 6, 553-556	4	11
74	Sleep attacks and dopamine agonists for Parkinson's disease: what is currently known?. <i>CNS Drugs</i> , 2003 , 17, 593-600	6.7	11
73	Neurosurgery for Parkinson's disease. <i>Seminars in Neurology</i> , 2001 , 21, 91-101	3.2	11
72	Magnetic resonance imaging of neurodegenerative diseases 1994 , 4, 146-58		11
71	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. <i>Neurology</i> , 2021 , 97, 942-957	6.5	11
70	The challenge of developing adenosine A antagonists for Parkinson disease: Istradefylline, praladenant, and tozadenant. <i>Parkinsonism and Related Disorders</i> , 2020 , 80 Suppl 1, S54-S63	3.6	10
69	Treatment of early Parkinson's disease. Part 1. <i>European Neurology</i> , 2009 , 61, 193-205	2.1	10
68	Treatment of early Parkinson's disease. Part 2. <i>European Neurology</i> , 2009 , 61, 206-15	2.1	10
67	Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations. <i>Movement Disorders</i> , 2010 , 25, 927-31	7	10
66	Chorea as a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome Type 1. <i>Clinical Rheumatology</i> , 2008 , 27, 389-90	3.9	10
65	Role of the pharmacist in the effective management of wearing-off in Parkinson's disease. <i>Annals of Pharmacotherapy</i> , 2007 , 41, 1842-9	2.9	10

64	Topiramate-induced psychosis in patients with essential tremor: report of 2 cases. <i>Clinical Neuropharmacology</i> , 2006 , 29, 168-9	1.4	10
63	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019 , 62, 201-209	3.6	9
62	Targeting neurons in the gastrointestinal tract to treat Parkinson's disease. <i>Clinical Parkinsonism & Related Disorders</i> , 2019 , 1, 2-7	0.9	9
61	Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. <i>Movement Disorders</i> , 2017 , 32, 1335-1336	7	9
60	Delayed thalamic intracranial hemorrhage in an essential tremor patient following deep brain stimulation. <i>European Neurology</i> , 2008 , 59, 187-9	2.1	9
59	Botulinum toxin A for the treatment of cervical dystonia. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 2017-24	4	9
58	Management of early Parkinson's disease. <i>Medical Clinics of North America</i> , 1999 , 83, 393-414, vi	7	9
57	Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. <i>CNS Spectrums</i> , 2020 , 1-10	1.8	9
56	Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials. <i>Journal of Parkinson's Disease</i> , 2019 , 9, 591-600	5.3	8
55	A 500U/2mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia. <i>International Journal of Neuroscience</i> , 2018 , 128, 619-626	2	8
54	Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2018 , 14, 839-845	3.1	8
53	Tiagabine and exacerbation of essential tremor. <i>Movement Disorders</i> , 2007 , 22, 2132-3	7	8
52	Manganese and chronic liver disease. <i>Movement Disorders</i> , 1996 , 11, 589	7	7
51	Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies. <i>Frontiers in Neurology</i> , 2020 , 11, 576117	4.1	7
50	Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017 , 373, 116-123	3.2	6
49	Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. <i>Parkinsonism and Related Disorders</i> , 2016 , 33, 127-133	3.6	6
48	Valbenazine for the treatment of tardive dyskinesia. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1279-1287	4	6
47	Levetiracetam for the treatment of essential tremor. <i>Movement Disorders</i> , 2005 , 20, 640	7	6

46	Amantadine ER (Gocovri) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021 , 12, 645706	4.1	6
45	A Clinically Interpretable Computer-Vision Based Method for Quantifying Gait in Parkinson's Disease. <i>Sensors</i> , 2021 , 21,	3.8	6
44	Use, maintenance and dose effects of cognitive speed of processing training in Parkinson's disease. <i>International Journal of Neuroscience</i> , 2017 , 127, 841-848	2	5
43	Treatment of chorea with levetiracetam. <i>European Journal of Clinical Pharmacology</i> , 2006 , 62, 87	2.8	5
42	A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020 , 81, 144-150	3.6	5
41	Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North America. <i>Npj Parkinson's Disease</i> , 2021 , 7, 34	9.7	5
40	Higher neuron densities in the cerebral cortex and larger cerebellums may limit dive times of delphinids compared to deep-diving toothed whales. <i>PLoS ONE</i> , 2019 , 14, e0226206	3.7	5
39	α-Synuclein in Parkinson's disease: getting to the core of the matter. <i>Lancet Neurology</i> , 2015 , 14, 785-786	24.1	4
38	Communicating with participants during the conduct of multi-center clinical trials. <i>Clinical Trials</i> , 2016 , 13, 592-596	2.2	4
37	Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials. <i>Journal of Parkinson's Disease</i> , 2021 , 11, 1663-1675	5.3	4
36	The UPDRS-8: a brief clinical assessment scale for Parkinson's disease. <i>International Journal of Neuroscience</i> , 2012 , 122, 333-7	2	3
35	Vascular hemichorea/hemiballismus and topiramate. <i>Movement Disorders</i> , 2006 , 21, 581; author reply 582	7	3
34	Depression in Patients with Parkinson's Disease. <i>CNS Drugs</i> , 2000 , 13, 253-264	6.7	3
33	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020 , 80, 127-132	3.6	3
32	Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson's Disease and Dyskinesia. <i>Neurology and Therapy</i> , 2021 , 10, 739-754	4.6	3
31	Patterns and predictors of referrals to allied health services for individuals with Parkinson's disease: A Parkinson's foundation (PF) QII study. <i>Parkinsonism and Related Disorders</i> , 2021 , 83, 115-122	3.6	3
30	45 Long-term Treatment with Deutetrabenazine Is Associated with Continued Improvement in Tardive Dyskinesia: Results from an Open-label Extension Study. <i>CNS Spectrums</i> , 2019 , 24, 200-201	1.8	2
29	Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's disease. <i>Evidence-Based Medicine</i> , 2015 , 20, 17		2

28	Levetiracetam for stiff-person syndrome: report of 2 patients. <i>Clinical Neuropharmacology</i> , 2008 , 31, 301-2	1.4	2
27	Future therapies for Parkinson's disease. <i>Neurologic Clinics</i> , 2004 , 22, S149-66	4.5	2
26	Demonstration of a sensory trick in a case of writer's cramp. <i>Movement Disorders</i> , 2002 , 17, 427-427	7	2
25	Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia. <i>Neurology and Therapy</i> , 2021 , 10, 307-320	4.6	2
24	On demand therapy for Parkinson's disease patients: Opportunities and choices. <i>Postgraduate Medicine</i> , 2021 , 133, 721-727	3.7	2
23	Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study. <i>PLoS ONE</i> , 2021 , 16, e0245827	3.7	2
22	46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension Study. <i>CNS Spectrums</i> , 2019 , 24, 201-201	1.8	1
21	Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment.. <i>Neurology and Therapy</i> , 2022 ,	4.6	1
20	134 Long-Term Deutetrabenazine Treatment Is Associated with Sustained Treatment Response in Tardive Dyskinesia: Results from an Open-Label Extension Study. <i>CNS Spectrums</i> , 2020 , 25, 284-285	1.8	1
19	Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial. <i>Movement Disorders</i> , 2021 , 36, 2408-2412	7	1
18	Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®). <i>Parkinsonism and Related Disorders</i> , 2021 , 82, 133-137	3.6	1
17	Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice. <i>Parkinson's Disease</i> , 2021 , 2021, 2603641	2.6	1
16	Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 915-925	5.3	0
15	Potential utility of amantadine DR/ER in persons with Parkinson's disease meeting 5-2-1 criteria for device aided therapy.. <i>Clinical Parkinsonism & Related Disorders</i> , 2022 , 6, 100123	0.9	0
14	Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. <i>Parkinsonism and Related Disorders</i> , 2020 , 77, 141-145	3.6	0
13	Help cure Parkinson's disease: please don't waste the Golden Year. <i>Npj Parkinson's Disease</i> , 2018 , 4, 29	9.7	0
12	P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease.. <i>Advances in Therapy</i> , 2022 , 1	4.1	0
11	Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease.. <i>Npj Parkinson's Disease</i> , 2022 , 8, 29	9.7	0

10	Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine.. <i>Parkinsonism and Related Disorders</i> , 2022 , 97, 47-51	3.6	0
9	0617 Solriamfetol Treatment of Excessive Daytime Sleepiness in Parkinson Disease: Results from a Phase 2 Proof-of-Concept Trial. <i>Sleep</i> , 2019 , 42, A245-A246	1.1	
8	34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities. <i>CNS Spectrums</i> , 2019 , 24, 193-193	1.8	
7	35 Long-term Improvements in Site-Rated Outcomes with Deutetrabenazine Treatment in Patients with Tardive Dyskinesia. <i>CNS Spectrums</i> , 2019 , 24, 193-194	1.8	
6	Reply to: Letter to Editor by Chaudhuri, Jenner, Antonini. <i>Movement Disorders</i> , 2020 , 35, 901	7	
5	Reply: Intravenous glutathione in Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 962-963	7	
4	Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary): Results of a Nationwide Dose Conversion Survey. <i>Parkinson Disease</i> , 2021 , 2021, 6638088	2.6	
3	149 Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study. <i>CNS Spectrums</i> , 2018 , 23, 92-93	1.8	
2	134 Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies. <i>CNS Spectrums</i> , 2018 , 23, 84-84	1.8	
1	158 Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study. <i>CNS Spectrums</i> , 2018 , 23, 97-97	1.8	